Palovarotene budget impact analysis: sponsor and CADTH base cases
“The sponsor estimated that the 3-year budget impact of reimbursing palovarotene to reduce the formation of HO in patients with FOP (females aged 8 years and older; males aged 10 years and older) would be $10,429,302 (year 1: $3,002,028; year 2: $3,472,745; year 3: $3,954,529).” (opens the source at this quote in a new tab)
“In the CADTH base case, the 3-year budget impact is expected to be $14,336,341 (year 1: $4,288,612; year 2: $4,775,024; year 3: $5,272,705) should palovarotene be reimbursed as per the Health Canada indication (i.e., to reduce the formation of HO in adults and children aged 8 years and older for females and 10 years and older for males with FOP).” (opens the source at this quote in a new tab)